Here are the latest reported weight-loss results for retatrutide (Eli Lilly’s “triple G” drug) from recent news coverage:
Most recent trial readouts (reported in May 2026)
- A new report says all tested retatrutide doses (4 mg, 9 mg, 12 mg) met primary and key secondary endpoints at 80 weeks, with “clinically meaningful” weight loss.[4]
- Another news report (citing Lilly) states an average weight loss of about 70.3 lb over 80 weeks, and that 45% of patients on the 12 mg dose lost up to 30% of body weight.[7]
- Reporters also note the results were not yet peer-reviewed at the time of the coverage, and that Eli Lilly indicated a potential path toward FDA filing later (reported as late 2027 or early 2028).[7]
Earlier Phase 3 highlight (reported in Dec 2025)
- A Phase 3 update (68-week study, per coverage) reported up to 28.7% average weight loss among participants who took the highest dose and stayed on treatment; and 23.7% when including all treated participants (including those who discontinued).[1]
Side effects (as commonly reported alongside the trial updates)
- Coverage describing the recent results says the most common side effects were gastrointestinal, including nausea, diarrhea, and vomiting, with some reports of urinary tract infection or skin discomfort.[7]
If you tell me whether you want (a) “best weight loss numbers,” (b) safety/tolerability, or (c) “how it compares to Zepbound/Semaglutide,” I can summarize that angle specifically.
Sources
People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.
www.nytimes.comEli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too much weight.
www.statnews.comThe results of the drug are comparable to what is seen with bariatric surgery, according to Eli Lilly.
abcnews.comEli Lilly's retatrutide, a GIP/GLP-1/glucagon agonist weight loss drug, yields strong clinical trial results for obesity. Significant weight loss seen. Newsradio 1140 WRVA
www.audacy.comEli Lilly's retatrutide, a GIP/GLP-1/glucagon agonist weight loss drug, yields strong clinical trial results for obesity. Significant weight loss seen.
www.audacy.com"Retatrutide delivered powerful weight loss," Leerink Partners analyst David Risinger told investors on Thursday morning. The study's results are the latest signal that retatrutide may be the most effective weight-loss medication in development. As such, retatrutide is a highly anticipated addition to Lilly's (LLY) obesity portfolio, which already includes Zepbound, a weekly GLP-1/GIP shot, and Foundayo, a daily non-peptide GLP-1 pill. It is sometimes referred to as "triple G" because it...
www.morningstar.comLilly’s triple weight loss combination therapy retatrutide has shown 28.7% weight loss in Phase 3, but higher discontinuations vs. tirzepatide and semaglutide.
european-biotechnology.comPeople treated with injections of retatrutide—an agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors—lost substantially more weight than those who received a placebo, according to results from a phase 2 trial involving 338 adults with obesity or...
jamanetwork.comFindings demonstrated that participants with obesity lost more than 24% of their starting body weight within 48 weeks of treatment with the highest dose of retatrutide. Additionally, 100% of the participants taking either of the two higher doses (8 mg and 12 mg) lost at least 5% or more of their body weight. The results indicate that retatrutide has an overall safety and tolerability profile similar to other nutrient-stimulated hormone-based therapies, such as GLP-1 receptor agonists approved...
diabetes.org